D-Index & Metrics Best Publications
Tsutomu Takeuchi

Tsutomu Takeuchi

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 83 Citations 26,554 615 World Ranking 8275 National Ranking 195

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Gene
  • Disease

Tsutomu Takeuchi spends much of his time researching Internal medicine, Rheumatoid arthritis, Surgery, Gastroenterology and Immunology. His study connects Placebo and Internal medicine. His Rheumatoid arthritis study incorporates themes from Methotrexate, Arthritis, Clinical endpoint, Randomized controlled trial and Rheumatism.

The Surgery study combines topics in areas such as Severity of illness, Risk factor and Rheumatoid factor. His Gastroenterology research also works with subjects such as

  • Pneumocystis pneumonia which connect with Pneumonitis,
  • Eye disease most often made with reference to Pathology. His Immunology research focuses on Endocrinology and how it relates to Immunoglobulin G.

His most cited work include:

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (3425 citations)
  • Innate production of T H 2 cytokines by adipose tissue-associated c-Kit + Sca-1 + lymphoid cells (1359 citations)
  • Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force (730 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Internal medicine, Rheumatoid arthritis, Immunology, Gastroenterology and Rheumatology. Tsutomu Takeuchi has researched Internal medicine in several fields, including Placebo and Surgery. The various areas that he examines in his Rheumatoid arthritis study include Methotrexate, Arthritis, Randomized controlled trial, Infliximab and Physical therapy.

The study incorporates disciplines such as Adalimumab, Discontinuation and Pharmacology in addition to Methotrexate. His Rheumatology research is multidisciplinary, incorporating perspectives in Rheumatism and Etanercept. Tsutomu Takeuchi combines subjects such as Molecular biology and Antigen with his study of Antibody.

He most often published in these fields:

  • Internal medicine (45.39%)
  • Rheumatoid arthritis (37.81%)
  • Immunology (26.49%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (45.39%)
  • Rheumatoid arthritis (37.81%)
  • In patient (12.49%)

In recent papers he was focusing on the following fields of study:

Internal medicine, Rheumatoid arthritis, In patient, Gastroenterology and Bristol-Myers are his primary areas of study. Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Placebo. His Rheumatoid arthritis research is multidisciplinary, relying on both Methotrexate, Discontinuation, Phases of clinical research, Arthritis and Adverse effect.

His Gastroenterology research integrates issues from Biomarker, Rheumatoid factor, Refractory and Glucocorticoid. Tsutomu Takeuchi has included themes like Acr20 response, Disease characteristics, Signs and symptoms, Safety profile and Study drug in his Bristol-Myers study. Tsutomu Takeuchi studied Disease and Immunology that intersect with Cytotoxic T cell.

Between 2018 and 2021, his most popular works were:

  • Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment (100 citations)
  • Translating IL-6 biology into effective treatments. (68 citations)
  • Effect of Filgotinib vs Placebo on Clinical Response in Patients with Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial (65 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Gene
  • Disease

His scientific interests lie mostly in Internal medicine, Rheumatoid arthritis, Placebo, Rheumatology and Methotrexate. His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology. His studies deal with areas such as Adverse effect, Clinical trial, Discontinuation and Incidence as well as Rheumatoid arthritis.

His research investigates the connection between Placebo and topics such as Pulmonary embolism that intersect with issues in Mace. His Rheumatology study integrates concerns from other disciplines, such as Overlap syndrome, Immunology, Giant cell arteritis, Vasculitis and CD14. His studies in Methotrexate integrate themes in fields like Response rate, Adalimumab and Arthritis.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch.
Annals of the Rheumatic Diseases (2014)

3425 Citations

Innate production of T H 2 cytokines by adipose tissue-associated c-Kit + Sca-1 + lymphoid cells

Kazuyo Moro;Taketo Yamada;Masanobu Tanabe;Tsutomu Takeuchi.
Nature (2010)

1746 Citations

Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trial

Norihiro Nishimoto;Kazuyuki Yoshizaki;Nobuyuki Miyasaka;Kazuhiko Yamamoto.
Arthritis & Rheumatism (2004)

1124 Citations

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

Josef S Smolen;Ferdinand C Breedveld;Gerd R Burmester;Vivian Bykerk.
Annals of the Rheumatic Diseases (2016)

1121 Citations

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

Norihiro Nishimoto;Jun Hashimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto.
Annals of the Rheumatic Diseases (2007)

957 Citations

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

Norihiro Nishimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto;Shinichi Kawai.
Modern Rheumatology (2009)

478 Citations

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

Tsutomu Takeuchi;Y. Tatsuki;Y. Nogami;N. Ishiguro.
Annals of the Rheumatic Diseases (2008)

413 Citations

An Evolutionarily Conserved Mechanism for MicroRNA-223 Expression Revealed by MicroRNA Gene Profiling

Taro Fukao;Yoko Fukuda;Kotaro Kiga;Jafar Sharif.
Cell (2007)

413 Citations

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

Norihiro Nishimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto;Shinichi Kawai.
Annals of the Rheumatic Diseases (2009)

408 Citations

Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.

Yoshihiko Hoshida;Jing Xian Xu;Shigeki Fujita;Itsuko Nakamichi.
The Journal of Rheumatology (2007)

406 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Tsutomu Takeuchi

Yoshiya Tanaka

Yoshiya Tanaka

University of Occupational and Environmental Health Japan

Publications: 146

Paul Emery

Paul Emery

University of Leeds

Publications: 130

Josef S. Smolen

Josef S. Smolen

Medical University of Vienna

Publications: 121

Tomoyoshi Nozaki

Tomoyoshi Nozaki

University of Tokyo

Publications: 114

Atsushi Kawakami

Atsushi Kawakami

Nagasaki University

Publications: 88

Kazuo Tsubota

Kazuo Tsubota

Keio University

Publications: 76

Tore K. Kvien

Tore K. Kvien

University of Oslo

Publications: 73

Désirée van der Heijde

Désirée van der Heijde

Leiden University Medical Center

Publications: 72

Bruno Fautrel

Bruno Fautrel

Université Paris Cité

Publications: 69

George C. Tsokos

George C. Tsokos

Beth Israel Deaconess Medical Center

Publications: 68

Xavier Mariette

Xavier Mariette

University of Paris-Sud

Publications: 67

Bernard Combe

Bernard Combe

University of Montpellier

Publications: 67

Ronald F. van Vollenhoven

Ronald F. van Vollenhoven

University of Amsterdam

Publications: 65

Laure Gossec

Laure Gossec

Sorbonne University

Publications: 65

Iain B. McInnes

Iain B. McInnes

University of Glasgow

Publications: 63

Daniel Aletaha

Daniel Aletaha

Medical University of Vienna

Publications: 62

Trending Scientists

Craig A. Tovey

Craig A. Tovey

Georgia Institute of Technology

Mansor Bin Ahmad

Mansor Bin Ahmad

Universiti Putra Malaysia

Mitsutaka Okumura

Mitsutaka Okumura

Osaka University

Kabir-ud-Din

Kabir-ud-Din

Aligarh Muslim University

Makoto Egashira

Makoto Egashira

Nagasaki University

Ulrich M. Zanger

Ulrich M. Zanger

Robert Bosch (Germany)

Shoshi Kikuchi

Shoshi Kikuchi

University of Tsukuba

Martin Konvicka

Martin Konvicka

Czech Academy of Sciences

David W. Carmichael

David W. Carmichael

King's College London

Chris Baeken

Chris Baeken

Eindhoven University of Technology

William Guido

William Guido

University of Louisville

Michael B. Chancellor

Michael B. Chancellor

University of Pittsburgh

Paul W. Armstrong

Paul W. Armstrong

University of Alberta

Karla Zadnik

Karla Zadnik

The Ohio State University

HA Henny Romijn

HA Henny Romijn

Eindhoven University of Technology

Something went wrong. Please try again later.